Open AccessInforming Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis
Author(s) -
Natalie Schwehr Mac Arthur,
Karen M. Kuntz,
Eva A. Enns,
Nathan D. Shippee,
Elaine Kingwell,
Helen Tremlett,
Adam Carpenter,
Mary Butler
Publication year - 2020
Publication title -
drugs and aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 94
eISSN - 1179-1969
pISSN - 1170-229X
DOI - 10.1007/s40266-019-00741-1
Subject(s) - medicine , discontinuation , natalizumab , fingolimod , multiple sclerosis , pediatrics , expanded disability status scale , quality of life (healthcare) , physical therapy , psychiatry , nursing
For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued.